Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.47 | N/A | +6.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.47 | N/A | +6.61% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on operational performance. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in key therapeutic areas.
They expressed confidence in ongoing product pipelines.
Amgen's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 1.56%, likely due to the lack of revenue details and guidance. Investors may be cautious as they await more information on future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 23, 2018